Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp 2242 viirus / vcp1529 viirus / vcp1533 viirus / vcp3011 viirus - immunoloogilised ravimid, live viral vaccines hobuste gripi viirus - hobused - aktiivse immuniseerimise hobuse nelja kuu vanuste või vanemate hobuste gripi vastu, et vähendada kliinilisi tunnuseid ja viiruse eritumist pärast nakatumist.

Euroopa Liit - eesti - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - sead - sigade aktiivseks immuniseerimiseks alates 7. elunädalast, et vältida suremust ja vähendada sigade katku viiruse (csfv) põhjustatud nakkust ja haigusi. onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - kana - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Euroopa Liit - eesti - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaktsiinid - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Euroopa Liit - eesti - EMA (European Medicines Agency)

gsk vaccines s.r.l. - välimine membraan, villid alates neisseria meningitidis 'e grupp b (tüvi nz 98/254), rekombinantse neisseria meningitidis' e grupp b fhbp fusion valk, rekombinantse neisseria meningitidis 'e grupp b nada valk, rekombinantse neisseria meningitidis' e grupp b nhba fusion valk - meningiit, meningokokk - meningokoki vaktsiinid - neisseria meningitidis serogrupi-b tüvede põhjustatud invasiivse haiguse aktiivne immuniseerimine.

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (mahoney strain), type 2 (mef-1 strain), type 3 (saukett strain)), hepatitis b surface antigen - hepatitis b; tetanus; immunization; whooping cough; poliomyelitis; diphtheria - vaktsiinid - infanrix penta on näidustatud esmaseks ning imikute difteeria, teetanuse, läkaköha, b-hepatiidi ja poliomüeliidi vastu.

Euroopa Liit - eesti - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - sigalaste immunoloogilised omadused - sead (nuumamiseks) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - kana - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ceva santé animale - geneetiliselt muundatud rekombinantse shiga-toksiini-2e-antigeeni - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - sead - escherichia coli (stec) poolt toodetud shiga toksiini 2e põhjustatud tursehaiguse suremuse ja kliiniliste tunnuste vähendamiseks põrsaste aktiivne immuniseerimine nelja päeva vanusest. immuunsuse tekkimine: 21 päeva pärast vaktsineerimist. immuunsuse kestus: 105 päeva pärast vaktsineerimist.

Eesti - eesti - Ravimiamet

aj vaccines a/s - tuberkuloosi tekitaja, elus, nõrgestatud - süstesuspensiooni pulber ja lahusti - 0,75mg 10tk